Project Description

Asparkam -L

solution for infusions 400 ml – Solutio pro infusionibus “Asparkam-L”

international nonproprietary name

Potassium and magnesium aspartate.

Potassium aspartate. Magnesium aspartate.



Pharmacotherapeutic group

Metabolics. Preparations of potassium and magnesium. Antiarrhytmic agents.Electrolytic solutions for intravenous injections.

Composition of the preparation

1 l solution for infusions contains potassium aspartate – 11,6 g, a magnesium aspartate – 7,9 g, Sorbite – 20 g.

Pharmacological action


The preparation promotes elimination of potassium and a magnesium deficiency, has antiarrhytmic effect, improves metabolism in myocardium, normalizes electrolytic balance. It is the donor of potassium and magnesium ions, promotes their penetration into intracellular space. Acting in cells, L-aspartate joins in processes of metabolism. Use of L- aspartate instead of DL- aspartate favors depression of the preparation toxicity. Ions Mg++reduce excitability of neurons, slow down neuromuscular transmission, participate in many enzymatic reactions, activate Na+-K+-ATPase, excreting Na+ and returning K+ to a cell, reduce Na+ concentration, prevents exchange Na+ on Ca++ in unstriated vessels muscles, lowering their resistance. Ions of K+ stimulate synthesis of ATP, glycogen, proteins, acetylcholine, etc., reduce excitability and conduction of myocardium, and at high concentration oppress automatism. Both of ions participate in intracellular osmotic pressure maintenance, processes of transfer and transmission of nervous impulses, contraction of skeletal muscles.


Ions K+and Mg++ are quickly and fully absorbed and distributed in all tissues of an organism. Concentration of ions of potassium in plasma remains increased not so long because of its fast entering inside of cells and excretion from an organism. The appreciable part of magnesium ions in plasma (25-30 %) forms complex compounds with proteins. Ions K+ and Mg++ are excreted mainly with urine, in small amounts – with excrements, sweat, tears, etc. At kidneys failure the function of magnesium and potassium elimination ions can be slowed down.

As acid-forming residue L- aspartate acid is endogenous compound and consequently possesses higher rate of redistribution in an organism that can provide higher bioavailability.


Indications of the preparation application are: arrhythmias caused by hypopotassemia, arrhythmias at intoxication  by cardiac glycosides, ventricular premature beats; stenocardia, myocardial infarction, heart failure (as an adjuvant agent); correction of hypopotassemia (caused by saluretics, laxatives, steroid hormones, chronic vomiting, etc.). The preparation is applied also for preliminary and subsequent therapy of cardiosurgery patients.

special indication

Strophanthin or preparations of digitalis can be administrated together with «Asparkam-L» solution for infusions  in case of need.

special warning

Not established

Dosage and method of administration

The preparation is entered intravenously dropwisely per 300-500 ml of solution 1-2 times a day with rate of 20-25 drops in a minute. The dose and duration of the preparation infusion is determined individually depending on indications and a degree of hyperpotassemia. For a week before and after cardiosurgery interventions should be entered per 300-500 ml a day daily.


Signs: hyperpotassemia (bradycardia, arrhythmia, ABP  reduction, vascular collapse, diastolic arrest of cardiac activity, neurotoxic signs) and hypermagnesemia (nausea, vomiting, lethargy, weakness of urinary bladder, impairement of atrioventricular conduction and ventricular spread of activation, at higher concentration of ions Mg++in plasma – ABP reduction, respiration paralysis, «magnesia narcosis», at extremely high concentration – diastolic arrest of cardiac activity).

Treatment: intravenous introduction of calcium and sodium salts solutions, intravenous dropwise  introduction of glucose with insulin (1 UNIT of insulin per 3-5 g of glucose). At peripheric paresises caused by toxic action of Mg++ ions, especially at paralysis of respiratory muscles, introduction of physostigmine is possible. At presence of renal failure extrarenal elimination can be carried out by hemodialysis or peritoneal dialysis.

safety measures

Not established

Side effects

Nausea, giddiness, abnormality of intraventricular conduction, face reddening, phlebitis,  reduction of arterial pressure, hyporeflexia, respiratory depression, convulsions are possible at the preparation introduction.


Reduces effect of cardiac glycosides. Simultaneous prescription of potassium-sparing diuretics can lead to hyperpotassemia and hypermagnesemia. At mixing with others injection solutions can arise turbidity or opalescence, such admixtures does not permitted to infuse.

Interactions with other medicinal preparations

Combined administration of Antisclerol with nitrates, Amiodaron, Sotalolom, Atenolol, Metoprolol, Verapamilum, Diltiazem, inhibitors of АPF(Captopril, Enalapril, Fosinopril), diuretics (Hydrochlorothiazide, Furosemide, Indapamide), Nifedipine, Dipiridamolum, Ticlopidine, Mildronate, Trimetazidine, terazonime, Phenazepame, vitamins is possible.

The preparation decreases side effects on gastrointestinal tract mucosa by nonsteroid anti-inflammatory agent.

The form of release

Solution for infusions in glass bottles per 400 ml.